FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2417406581> ?p ?o ?g. }

• W2417406581 startingPage "337" @default.
• W2417406581 abstract "PURPOSE Single-agent docetaxel and ifosfamide are clinically active in anthracycline-pretreated advanced breast cancer. We conducted a phase I-II study aiming to define the maximum tolerated dose (MTD), the dose-limiting toxicities (DLTs), and the activity of the docetaxel-ifosfamide combination in this setting. PATIENTS AND METHODS Cohorts of 3-6 patients with histologically confirmed metastatic breast cancer after prior anthracycline-based chemotherapy were treated at successive dose levels (DLs) with escalated doses of docetaxel (70-100 mg/m(2) over 1 h on day 1), followed by ifosfamide 5-6 g/m(2) divided over days 1 and 2 (2.5-3.0 g/m(2)/day over 1 h), and recycled every 21 days. G-CSF was added once dose-limiting neutropenia was encountered at a certain DL and planned to be incorporated prophylactically in subsequent higher DLs. RESULTS Sixty-five patients (median age 57 years, range 32-72) and performance status (PS) (World Health Organization-WHO) of 1 (range 0-2) were treated at 5 DLs as follows: 21 in phase I DLs (DL1: 3, DL2: 6, DL3: 3, DL4: 6, and DL5: 3) and the remaining 44 were treated at DL4 (total of 50 patients at DL4), which was defined as the level for phase II testing. All patients were evaluable for toxicity and 62 for response. DLT (with the addition of G-CSF after DL2) was reached at DL5 with 2/3 initial patients developing febrile neutropenia. Clinical response rates (RRs), on an intention-to-treat basis, in phase II were 56% (95% CI 42.2-69.7): complete remission (CR) 4, partial remission (PR) 24, stable disease (SD) 10 and progressive disease (PD) 12. The median response duration was 7 months (range 3-24), the median time to progression (TTP) 6.5 months (range 0.1-26), and the median overall survival (OS) 13 months (range 0.1-33). Grade 3/4 toxicities included neutropenia in 72% of patients-with 60% developing grade 4 neutropenia (</= 7 days) and 10% of these febrile neutropenia (FN), while no grade 3/4 thrombocytopenia was observed. Other toxicities included grade 2 peripheral neuropathy only in 10% of the patients, grade 1/2 reversible CNS toxicity in 16%, no renal toxicity, grade 2 myalgias in 8%, grade 3 diarrhea in 8%, skin/nail toxicity in 14%, and grade 2 fluid retention in 2%. One patient treated at the phase II part of the study died of acute liver failure after the first cycle. CONCLUSION The present phase I-II study determined the feasibility, defined the MTD and demonstrated the encouraging activity of the docetaxel-ifosfamide combination in the phase II part of the study. Therefore, future randomized phase III studies versus single-agent docetaxel or combinations of the latter with other active agents are warranted." @default.
• W2417406581 created "2016-06-24" @default.
• W2417406581 creator A5001577925 @default.
• W2417406581 creator A5004016557 @default.
• W2417406581 creator A5025611857 @default.
• W2417406581 creator A5028501800 @default.
• W2417406581 creator A5029045590 @default.
• W2417406581 creator A5064667083 @default.
• W2417406581 creator A5066518344 @default.
• W2417406581 creator A5075071777 @default.
• W2417406581 creator A5077706957 @default.
• W2417406581 creator A5090151031 @default.
• W2417406581 date "2005-07-01" @default.
• W2417406581 modified "2023-09-24" @default.
• W2417406581 title "Dose escalation of docetaxel and ifosfamide in patients with advanced breast cancer failing prior anthracyclines: mature results of a phase I-II study." @default.
• W2417406581 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17357187" @default.
• W2417406581 hasPublicationYear "2005" @default.
• W2417406581 type Work @default.
• W2417406581 sameAs 2417406581 @default.
• W2417406581 citedByCount "0" @default.
• W2417406581 crossrefType "journal-article" @default.
• W2417406581 hasAuthorship W2417406581A5001577925 @default.
• W2417406581 hasAuthorship W2417406581A5004016557 @default.
• W2417406581 hasAuthorship W2417406581A5025611857 @default.
• W2417406581 hasAuthorship W2417406581A5028501800 @default.
• W2417406581 hasAuthorship W2417406581A5029045590 @default.
• W2417406581 hasAuthorship W2417406581A5064667083 @default.
• W2417406581 hasAuthorship W2417406581A5066518344 @default.
• W2417406581 hasAuthorship W2417406581A5075071777 @default.
• W2417406581 hasAuthorship W2417406581A5077706957 @default.
• W2417406581 hasAuthorship W2417406581A5090151031 @default.
• W2417406581 hasConcept C121608353 @default.
• W2417406581 hasConcept C126322002 @default.
• W2417406581 hasConcept C143998085 @default.
• W2417406581 hasConcept C2775930923 @default.
• W2417406581 hasConcept C2776694085 @default.
• W2417406581 hasConcept C2776802502 @default.
• W2417406581 hasConcept C2777063308 @default.
• W2417406581 hasConcept C2777506904 @default.
• W2417406581 hasConcept C2777511904 @default.
• W2417406581 hasConcept C2778119113 @default.
• W2417406581 hasConcept C2778850193 @default.
• W2417406581 hasConcept C2781190966 @default.
• W2417406581 hasConcept C31760486 @default.
• W2417406581 hasConcept C530470458 @default.
• W2417406581 hasConcept C71924100 @default.
• W2417406581 hasConceptScore W2417406581C121608353 @default.
• W2417406581 hasConceptScore W2417406581C126322002 @default.
• W2417406581 hasConceptScore W2417406581C143998085 @default.
• W2417406581 hasConceptScore W2417406581C2775930923 @default.
• W2417406581 hasConceptScore W2417406581C2776694085 @default.
• W2417406581 hasConceptScore W2417406581C2776802502 @default.
• W2417406581 hasConceptScore W2417406581C2777063308 @default.
• W2417406581 hasConceptScore W2417406581C2777506904 @default.
• W2417406581 hasConceptScore W2417406581C2777511904 @default.
• W2417406581 hasConceptScore W2417406581C2778119113 @default.
• W2417406581 hasConceptScore W2417406581C2778850193 @default.
• W2417406581 hasConceptScore W2417406581C2781190966 @default.
• W2417406581 hasConceptScore W2417406581C31760486 @default.
• W2417406581 hasConceptScore W2417406581C530470458 @default.
• W2417406581 hasConceptScore W2417406581C71924100 @default.
• W2417406581 hasIssue "3" @default.
• W2417406581 hasLocation W24174065811 @default.
• W2417406581 hasLocation W24174065812 @default.
• W2417406581 hasOpenAccess W2417406581 @default.
• W2417406581 hasPrimaryLocation W24174065811 @default.
• W2417406581 hasRelatedWork W1966786212 @default.
• W2417406581 hasRelatedWork W1975667445 @default.
• W2417406581 hasRelatedWork W1976701769 @default.
• W2417406581 hasRelatedWork W1987592374 @default.
• W2417406581 hasRelatedWork W2023956360 @default.
• W2417406581 hasRelatedWork W2028697269 @default.
• W2417406581 hasRelatedWork W2051767183 @default.
• W2417406581 hasRelatedWork W2056584284 @default.
• W2417406581 hasRelatedWork W2061492774 @default.
• W2417406581 hasRelatedWork W2064508141 @default.
• W2417406581 hasRelatedWork W2069469795 @default.
• W2417406581 hasRelatedWork W2164696024 @default.
• W2417406581 hasRelatedWork W2403018570 @default.
• W2417406581 hasRelatedWork W2416053208 @default.
• W2417406581 hasRelatedWork W2586228073 @default.
• W2417406581 hasRelatedWork W2886812170 @default.
• W2417406581 hasRelatedWork W2996211065 @default.
• W2417406581 hasRelatedWork W3007398524 @default.
• W2417406581 hasRelatedWork W2185829164 @default.
• W2417406581 hasRelatedWork W2484162028 @default.
• W2417406581 hasVolume "10" @default.
• W2417406581 isParatext "false" @default.
• W2417406581 isRetracted "false" @default.
• W2417406581 magId "2417406581" @default.
• W2417406581 workType "article" @default.